Metabolomic Insights from IV Ketamine in TRD: Bio-K/NNDC Trial

New Findings: Broad Metabolic Changes After IV Ketamine in TRD

The Bio-K/NNDC multicenter trial (ClinicalTrials.gov: NCT03156504) demonstrates that intravenous (IV) racemic ketamine induces extensive metabolic alterations in adults with treatment-resistant major depressive disorder (TRD). Conducted across multiple U.S. academic sites, the open-label study enrolled 69 adults, each receiving three ketamine infusions (0.5 mg/kg). Remission was defined as a Montgomery–Åsberg Depression Rating Scale (MADRS) score of 9 or less, 24 hours after the third infusion. Metabolomic profiling, using the Biocrates MxP® Q500 kit, captured over 600 metabolites at baseline and after infusions, providing one of the most comprehensive biochemical datasets for ketamine in TRD to date.

Mechanistic Insights: Neurotransmitter, Mitochondrial, and Endocrine Pathways

IV ketamine was associated with marked changes in several metabolic pathways, including neurotransmitter synthesis, mitochondrial function, and neuroendocrine signaling. Notably, after the first infusion, participants showed increased levels of acylcarnitines, cortisol, amino acids (such as glutamine, glycine, and branched-chain amino acids), and biogenic amines (including gamma-aminobutyric acid [GABA] and putrescine). Medium-chain acylcarnitines and glutamate levels decreased. After the third infusion, elevations in C16 acylcarnitine, serotonin, and GABA persisted, while cortisol levels normalized. These findings reinforce the hypothesis that ketamine’s rapid antidepressant effects involve not just glutamatergic modulation, but also broad shifts in mitochondrial energy metabolism and stress hormone regulation.

One non-obvious insight from this trial is the persistent elevation of GABA and serotonin after repeated ketamine dosing—a pattern not consistently observed in earlier, smaller studies. This suggests that repeated dosing may uniquely affect inhibitory and serotonergic systems, potentially informing future trial designs and mechanistic models.

Policy and Research Implications: No Validated Biomarkers Yet

Despite extensive metabolic profiling, the study did not identify any single metabolite or pattern of metabolite changes that could reliably predict clinical response to ketamine after correction for multiple comparisons. While remitters showed greater increases in GABA synthesis, no metabolite change correlated with MADRS improvement at a statistically significant level. This outcome underscores a key limitation for clinicians and regulators: although metabolomics deepens mechanistic understanding, it does not yet provide actionable biomarkers for patient selection, treatment monitoring, or regulatory endpoints.

For policymakers and research sponsors, these results highlight the need for larger, possibly multi-omic studies integrating genetics, proteomics, and metabolomics to identify robust predictors of response. The lack of validated biomarkers also means that regulatory guidance for ketamine in TRD will continue to rely primarily on clinical endpoints and safety data, rather than laboratory-based predictors.

Risks, Unknowns, and the Limits of Current Evidence

The trial confirms that ketamine’s biochemical effects are broad and multi-systemic, but it also exposes several important unknowns. First, the open-label design and relatively small sample size (n=69) limit the generalizability of the findings. Second, the absence of a placebo group means that some observed metabolic changes could reflect non-specific effects of repeated IV infusions or the hospital environment. Third, while the study documents metabolic correlates of ketamine exposure and remission, it does not establish causal mechanisms or long-term safety implications of these metabolic shifts.

Another practical risk is the potential for overinterpretation of metabolomic data in clinical settings. Without validated biomarkers, clinicians should avoid using metabolic profiles to guide ketamine treatment decisions outside of research protocols. The study also raises questions about the long-term impact of repeated ketamine-induced changes in mitochondrial and neurotransmitter pathways, which remain unexplored in this and most related trials.

Looking Ahead: Toward Translational Biomarkers and Personalized Psychiatry

The Bio-K/NNDC trial advances the field by mapping the complex metabolic landscape of ketamine treatment in TRD, but translation to clinical practice remains out of reach. Future research will need to integrate metabolomic findings with clinical, genetic, and neuroimaging data to develop predictive biomarkers and personalized treatment algorithms. For now, the primary value of these results lies in guiding hypothesis generation and informing the design of next-generation trials, rather than immediate clinical or regulatory application.

How we research: This article was written and reviewed by Dr. Alex R. Bennett, PhD (Neuropharmacology), on 2026-09-08. Primary sources include the original Bio-K/NNDC trial publication (OpenAlex) and the official ClinicalTrials.gov registry.